Filtered By:
Drug: Medroxyprogesterone
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 4 results found since Jan 2013.
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery
CONCLUSIONS: The association between ET and having no macroscopic residual disease is plausible given a strong underlying biologic hypothesis between this exposure and diagnosis with HGSC. If this or the parity finding is replicated, these factors could be included in risk stratification models to determine whether HGSC patients should receive PCS or neoadjuvant chemotherapy.PMID:36401943 | DOI:10.1016/j.ygyno.2022.10.018
Source: Ann Oncol - November 19, 2022 Category: Cancer & Oncology Authors: Minh Tung Phung Penelope M Webb Anna DeFazio Sian Fereday Alice W Lee David D L Bowtell Peter A Fasching Ellen L Goode Marc T Goodman Beth Y Karlan Jenny Lester Keitaro Matsuo Francesmary Modugno James D Brenton Toon Van Gorp Paul D P Pharoah Joellen M Sc Source Type: research
